PharmaLedger

PharmaLedger
PharmaLedger logo

FACTS & FIGURES

Start Date
End Date
Call
IMI2 - Call 15
Grant agreement number
853992

Type of Action: 
RIA (Research and Innovation Action)

Contributions
IMI Funding
8 290 694
EFPIA in kind
12 630 208
Total Cost
20 920 902

Summary

The most famous application of blockchain technology is the bitcoin currency, yet it could also revolutionise the way other sectors work. The goal of the PharmaLedger project is to deliver a blockchain-based platform for the healthcare sector, using the supply chain, clinical trials, and health data as case studies.

In blockchain technology, data is decentralised, meaning it is stored across multiple servers. It is also immutable; this means data records (or ‘blocks’) cannot be changed or tampered with. Each new ‘block’ of data is connected to the previous one, creating the ‘blockchain’. The blocks are connected by cryptography, making the system secure.

PharmaLedger aims to use these technologies to make blockchain in healthcare a reality thanks to a platform that is supported and trusted by different stakeholders and complies with existing and emerging laws and regulations. For this reason, the project brings together technical, legal, and regulatory experts as well as pharmaceutical companies and patient organisations.

Ultimately, the project hopes that bringing the blockchain into healthcare in this way will help to accelerate the delivery of innovation that benefits patients as well as the wider health ecosystem.

Participants Show participants on map

EFPIA companies
  • Abbvie Inc, North Chicago, Illinois, United States
  • Astrazeneca AB, Södertälje, Sweden
  • Bayer Aktiengesellschaft, Leverkusen, Germany
  • F. Hoffmann-La Roche AG, Basel, Switzerland
  • Glaxosmithkline Research And Development LTD., Brentford, Middlesex, United Kingdom
  • Janssen Pharmaceutica Nv, Beerse, Belgium
  • Merck Sharp & Dohme Corp, Whitehouse Station, New Jersey, United States
  • Novartis Pharma AG, Basel, Switzerland
  • Novo Nordisk A/S, Bagsvaerd, Denmark
  • Pfizer Limited, Sandwich, Kent , United Kingdom
  • UCB Biopharma SRL, Brussels, Belgium
Universities, research organisations, public bodies, non-profit groups
  • Dimokritio Panepistimio Thrakis, Komotini, Greece
  • Ethniko Kentro Erevnas Kai Technologikis Anaptyxis, Thermi Thessaloniki, Greece
  • Hospital Do Espirito Santo De Evora Epe, Evora, Portugal
  • Katholieke Universiteit Leuven, Leuven, Belgium
  • National Research And Development Institute For Cryogenics And Isotopic Technologies Icsi Rm Valcea, Ramnicu Valcea, Romania
  • Ospedale Pediatrico Bambino Gesu, Rome, Italy
  • Universidad Politecnica De Madrid, Madrid, Spain
  • Universitaetsklinikum Wuerzburg - Klinikum Der Bayerischen Julius-Maximilians-Universitat, Wuerzburg, Germany
Small and medium-sized enterprises (SMEs) and mid-sized companies (<€500 m turnover)
  • Arteevo Technologies LTD, Tel Aviv, Israel
  • Ekon Modeling Sofware Systems LTD*Ekon, Modi'in-Maccabim-Re'ut, Israel
  • Imprensa Nacional - Casa Da Moeda, S. A., Lisboa, Portugal
  • Onorach LTD, Dundee, United Kingdom
  • Pdm E Fc Projecto Desenvolvimento Manutencao Formacao E Consultadorialda, Lisboa, Portugal
  • Romsoft SRL, Iasi, Romania
  • Technovative Solutions LTD, Manchester, United Kingdom
Patient organisations
  • European Forum For Good Clinical Practice, Brussels, Belgium
  • European Patients’ Forum (EPF), Brussels, Belgium
Project coordinator
Maria Eugenia Beltran Jaunsaras
Universidad Politecnica De Madrid